IBDEI0HM ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8525,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Near Total
 ;;^UTILITY(U,$J,358.3,8525,1,4,0)
 ;;=4^369.13
 ;;^UTILITY(U,$J,358.3,8525,2)
 ;;=^268873
 ;;^UTILITY(U,$J,358.3,8526,0)
 ;;=369.14^^52^582^81
 ;;^UTILITY(U,$J,358.3,8526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8526,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Profound
 ;;^UTILITY(U,$J,358.3,8526,1,4,0)
 ;;=4^369.14
 ;;^UTILITY(U,$J,358.3,8526,2)
 ;;=^268874
 ;;^UTILITY(U,$J,358.3,8527,0)
 ;;=369.22^^52^582^102
 ;;^UTILITY(U,$J,358.3,8527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8527,1,3,0)
 ;;=3^Severe Impairment,Both Eyes
 ;;^UTILITY(U,$J,358.3,8527,1,4,0)
 ;;=4^369.22
 ;;^UTILITY(U,$J,358.3,8527,2)
 ;;=^268882
 ;;^UTILITY(U,$J,358.3,8528,0)
 ;;=369.60^^52^582^6
 ;;^UTILITY(U,$J,358.3,8528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8528,1,3,0)
 ;;=3^Blindness,One Eye Only
 ;;^UTILITY(U,$J,358.3,8528,1,4,0)
 ;;=4^369.60
 ;;^UTILITY(U,$J,358.3,8528,2)
 ;;=^268880
 ;;^UTILITY(U,$J,358.3,8529,0)
 ;;=369.9^^52^582^115
 ;;^UTILITY(U,$J,358.3,8529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8529,1,3,0)
 ;;=3^Visual Loss NOS
 ;;^UTILITY(U,$J,358.3,8529,1,4,0)
 ;;=4^369.9
 ;;^UTILITY(U,$J,358.3,8529,2)
 ;;=^126769
 ;;^UTILITY(U,$J,358.3,8530,0)
 ;;=377.61^^52^582^20
 ;;^UTILITY(U,$J,358.3,8530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8530,1,3,0)
 ;;=3^D/O Pathways w/ Neoplasm
 ;;^UTILITY(U,$J,358.3,8530,1,4,0)
 ;;=4^377.61
 ;;^UTILITY(U,$J,358.3,8530,2)
 ;;=^269241
 ;;^UTILITY(U,$J,358.3,8531,0)
 ;;=379.02^^52^582^68
 ;;^UTILITY(U,$J,358.3,8531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8531,1,3,0)
 ;;=3^Nodular Episcleritis
 ;;^UTILITY(U,$J,358.3,8531,1,4,0)
 ;;=4^379.02
 ;;^UTILITY(U,$J,358.3,8531,2)
 ;;=^269285
 ;;^UTILITY(U,$J,358.3,8532,0)
 ;;=379.07^^52^582^90
 ;;^UTILITY(U,$J,358.3,8532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8532,1,3,0)
 ;;=3^Posterior Scleritis
 ;;^UTILITY(U,$J,358.3,8532,1,4,0)
 ;;=4^379.07
 ;;^UTILITY(U,$J,358.3,8532,2)
 ;;=^269295
 ;;^UTILITY(U,$J,358.3,8533,0)
 ;;=379.92^^52^582^106
 ;;^UTILITY(U,$J,358.3,8533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8533,1,3,0)
 ;;=3^Swelling/Mass of Eye
 ;;^UTILITY(U,$J,358.3,8533,1,4,0)
 ;;=4^379.92
 ;;^UTILITY(U,$J,358.3,8533,2)
 ;;=^269334
 ;;^UTILITY(U,$J,358.3,8534,0)
 ;;=379.93^^52^582^94
 ;;^UTILITY(U,$J,358.3,8534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8534,1,3,0)
 ;;=3^Redness/Discharge of Eye
 ;;^UTILITY(U,$J,358.3,8534,1,4,0)
 ;;=4^379.93
 ;;^UTILITY(U,$J,358.3,8534,2)
 ;;=^104154
 ;;^UTILITY(U,$J,358.3,8535,0)
 ;;=379.99^^52^582^86
 ;;^UTILITY(U,$J,358.3,8535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8535,1,3,0)
 ;;=3^Oth Ill-Defined Eye D/O
 ;;^UTILITY(U,$J,358.3,8535,1,4,0)
 ;;=4^379.99
 ;;^UTILITY(U,$J,358.3,8535,2)
 ;;=^269335
 ;;^UTILITY(U,$J,358.3,8536,0)
 ;;=555.9^^52^582^95
 ;;^UTILITY(U,$J,358.3,8536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8536,1,3,0)
 ;;=3^Regional Enteritis,Unspec
 ;;^UTILITY(U,$J,358.3,8536,1,4,0)
 ;;=4^555.9
 ;;^UTILITY(U,$J,358.3,8536,2)
 ;;=^29356
 ;;^UTILITY(U,$J,358.3,8537,0)
 ;;=696.1^^52^582^93
 ;;^UTILITY(U,$J,358.3,8537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8537,1,3,0)
 ;;=3^Psoriasis
 ;;^UTILITY(U,$J,358.3,8537,1,4,0)
 ;;=4^696.1
 ;;^UTILITY(U,$J,358.3,8537,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,8538,0)
 ;;=709.2^^52^582^39
 ;;^UTILITY(U,$J,358.3,8538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8538,1,3,0)
 ;;=3^Facial Scar
 ;;^UTILITY(U,$J,358.3,8538,1,4,0)
 ;;=4^709.2
 ;;^UTILITY(U,$J,358.3,8538,2)
 ;;=^108131
 ;;^UTILITY(U,$J,358.3,8539,0)
 ;;=710.0^^52^582^60
